Relevant bibliographies by topics / Parkinson's Disease (AD)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Parkinson's Disease (AD)'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Parkinson's Disease (AD).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Parkinson's Disease (AD)"

1

Clarke, C. E. "Parkinson's disease." BMJ 335, no. 7617 (2007): 441–45. http://dx.doi.org/10.1136/bmj.39289.437454.ad.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jakubiec, Joanna, Julita Gmitrzuk, Zuzanna Malinka, et al. "The Impact of Gut Microbiota on Parkinson’s and Alzheimer’s Diseases: A Review of Medical Literature." Quality in Sport 15 (July 5, 2024): 52004. http://dx.doi.org/10.12775/qs.2024.15.52004.

Full text
Abstract:
Introduction Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), pose a major public health challenge due to their progressive nature and profound impact on patients and healthcare systems. Emerging evidence underscores the key role of the gut microbiota in the pathogenesis and progression of these diseases. This paper examines the current state of knowledge on the impact of the gut microbiota on PD and AD, focusing on mechanisms such as modulation of inflammation, blood-brain barrier integrity, neurotransmitter production and amyloid pathology. Future re
APA, Harvard, Vancouver, ISO, and other styles
3

Helsing, Elisabet. "The reluctant patient: Parkinson's disease." BMJ 335, no. 7627 (2007): 989–90. http://dx.doi.org/10.1136/bmj.39329.606840.ad.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Giovannetti, Tania, Priscilla Britnell, Laura Brennan, et al. "Everyday Action Impairment in Parkinson's Disease Dementia." Journal of the International Neuropsychological Society 18, no. 5 (2012): 787–98. http://dx.doi.org/10.1017/s135561771200046x.

Full text
Abstract:
AbstractThis study examined everyday action impairment in participants with Parkinson's disease dementia (PDD) by comparison with participants with Parkinson's disease-no dementia (PD) or Alzheimer's disease (AD) and in reference to a neuropsychological model. Participants with PDD (n = 20), PD (n = 20), or AD (n = 20) were administered performance-based measures of everyday functioning that allowed for the quantification of overall performance and error types. Also, caregiver ratings of functional independence were obtained. On performance-based tests, the PDD group exhibited greater function
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Yubu. "The Application and Effectiveness of CRISPR-Cas9 in Alzheimer's Disease and Parkinson's Disease." Highlights in Science, Engineering and Technology 102 (July 11, 2024): 514–19. https://doi.org/10.54097/pbjqff61.

Full text
Abstract:
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are both types of neurodegenerative diseases (ND) that lead to severe failure in the nervous system. Usually, AD and PD are caused by genetic or environmental factors, and patients of AD or PD suffer from life inconveniences. AD and PD are both the major causes of irreversible dementia and can be classified into familiar and sporadic. A greater proportion of patients get sporadic AD and PD, and there hasn’t been an effective treatment for the diseases. Widely discussed in the 21st century, it is believed that CRISPR-Cas9 gene therapy may be
APA, Harvard, Vancouver, ISO, and other styles
6

Ma, Xiaoyu, and Juejin Wang. "Research progress on the role of ginsenoside Rd in central nervous system diseases." African Health Sciences 24, no. 4 (2025): 325–31. https://doi.org/10.4314/ahs.v24i4.41.

Full text
Abstract:
Ginsenoside Rd (GSRd) is one of the rare saponin monomers extracted from ginseng. Most importantly, GSRd could effectively cross the intact blood-brain barrier (BBB). Studies have shown that it plays an important role in the treatment of neurological diseases such as ischemic stroke (IS), spinal cord injury (SCI), Alzheimer's disease (AD) and Parkinson's disease (PD). The results of these studies are of great significance for the clinical application of GSRd in the treatment in neurological diseases. This article reviewed the protective effects of GSRd in central nervous system diseases and an
APA, Harvard, Vancouver, ISO, and other styles
7

Oleksak, Izabela, Michał Leśniewski, Iwona Welian-Polus, Karolina Maliszewska, and Joanna Ziółkowska. "Does gut microbiota have an impact on the origin of Alzheimer's and Parkinson's disease? – literature review." Journal of Education, Health and Sport 57 (February 7, 2024): 70–85. http://dx.doi.org/10.12775/jehs.2024.57.005.

Full text
Abstract:
Introduction and purpose:
 Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development.
 Material and methods
 The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s d
APA, Harvard, Vancouver, ISO, and other styles
8

Liu, Meiqiu, Qian Jiao, Xixun Du, Mingxia Bi, Xi Chen, and Hong Jiang. "Potential Crosstalk Between Parkinson's Disease and Energy Metabolism." Aging and disease 12, no. 8 (2021): 2003. http://dx.doi.org/10.14336/ad.2021.0422.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Foley, Jennifer A., Reiner Kaschel, and Sergio Della Sala. "Dual Task Performance in Parkinson’s Disease." Behavioural Neurology 27, no. 2 (2013): 183–91. http://dx.doi.org/10.1155/2013/150361.

Full text
Abstract:
Several studies have found dual tasking to be impaired in Alzheimer's disease (AD), but unaffected by healthy ageing. It is not known if this deficit is specific to AD, or also present in other neurodegenerative disorders that can occur in later life, such as Parkinson's disease (PD). Therefore, this study investigated dual tasking in 13 people with PD, 26 AD and 42 healthy age-matched controls. The people with AD demonstrated a specific impairment in dual tasking, which worsened with increasing disease severity. The people with PD did not demonstrate any deficits in dual tasking ability, when
APA, Harvard, Vancouver, ISO, and other styles
10

Wingo, Thomas S., Ami Rosen, David J. Cutler, James J. Lah, and Allan I. Levey. "Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases." Neurobiology of Aging 33, no. 1 (2012): 204.e13–204.e15. http://dx.doi.org/10.1016/j.neurobiolaging.2010.08.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Parkinson's Disease (AD)"

1

Cavallieri, Francesco. "STUDIO SULL'ASSOCIAZIONE TRA SINTOMI ASSIALI, ALTERAZIONI COGNITIVE, VARIABILI CLINICO-STRUMENTALI DELLA FUNZIONE MOTORIA E DEPOSIZIONE DI BETA-AMILOIDE CEREBRALE IN PAZIENTI AFFETTI DA MALATTIA DI PARKINSON SOTTOPOSTI AD INTERVENTO DI STIMOLAZIONE CEREBRALE PROFONDA DEL NUCLEO SUBTALAMICO." Doctoral thesis, Università degli studi di Modena e Reggio Emilia, 2022. http://hdl.handle.net/11380/1278341.

Full text
Abstract:
Introduzione La stimolazione cerebrale profonda del nucleo subtalamico (STN-DBS) rappresenta un trattamento efficace a lungo termine nella malattia di Parkinson (MP) in fase avanzata. La STN-DBS consente un miglioramento duraturo di complicanze motorie, tremore e rigidità tuttavia con un effetto ridotto sui sintomi assiali (disturbi del cammino, dell'equilibrio, dell’eloquio e della deglutizione) e declino cognitivo, che rappresentano le principali cause di disabilità a lungo termine. Molti studi hanno analizzato i sintomi assiali nella MP con un approccio strumentale focalizzato unicamente su
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Dongdong. "Natural Product Chemical Probe Discovery against Parkinson’s Disease." Thesis, Griffith University, 2016. http://hdl.handle.net/10072/367616.

Full text
Abstract:
Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting over five million patients worldwide. Like Alzheimer’s disease (AD), it mostly affects the elderly and causes considerable disability and suffering. Unfortunately, the molecular mechanism of PD is still poorly understood, and there are no drugs available to treat the disease. Our overall aim was to identify natural products to probe PD by phenotypic assay using human olfactory neurosphere-derived (hONS) cells from PD patients. The research presented in this thesis exemplifies the importance of natural produ
APA, Harvard, Vancouver, ISO, and other styles
3

BAGNOLI, Sara. "Protein aggregation, ageing and neurodegeneration in the emerging model Nothobranchius furzeri." Doctoral thesis, Scuola Normale Superiore, 2021. http://hdl.handle.net/11384/108452.

Full text
Abstract:
The teleost Nothobranchius furzeri is an annual fish and is the shortest-lived vertebrate that can be cultured in captivity. The longer-lived strains of N. furzeri show a median lifespan of 40 weeks making it a unique model organism for ageing research. N. furzeri recapitulates the major features of mammalian brain ageing, such as gliosis, lipofuscin and iron accumulation and also more global changes at transcriptomic- and proteomic-level. Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Fronto-Temporal Dementia (FTD), are the prevalent causes of demen
APA, Harvard, Vancouver, ISO, and other styles
4

Boman, Andrea. "Lysosomal network proteins as biomarkers and therapeutic targets in neurodegenerative disease." Doctoral thesis, Linköpings universitet, Avdelningen för cellbiologi, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-122347.

Full text
Abstract:
The pre-symptomatic stage of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) occurs several decades before the clinical onset. Changes in the lysosomal network, i.e. the autophagosomal, endosomal and lysosomal vesicular system, are among the first alterations observed. There are currently no treatments to slow or cure neurodegenerative diseases, and there is a great need for discovery of treatment targets in cellular pathways where pathology pre-dates the neuronal death. It is also crucial to be able to diagnose neurodegenerative diseases earlier, both
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Parkinson's Disease (AD)"

1

International, Conference AP/PD (8th Salzburg Austria 2007). Alzheimer's and Parkinson's diseases: Progress and new perspectives, 8th International Conference AD/PD, Salzburg, Austria, March 14-18, 2007 : abstracts. Karger, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ryskamp, Daniel A., Elena Popugaeva, and Ilya Bezprozvanny. Calcium Hypothesis of Neurodegeneration. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0003.

Full text
Abstract:
Aged-related changes in neuronal physiology and stressors related to specific neurodegenerative diseases collude to undermine neuronal calcium homeostasis, which is a common pathological feature in the initiation and progression of Alzheimer’s disease(AD), Huntington’s disease (HD), Parkinson’s disease, amyotrophic lateral sclerosis, spinocerebellar ataxias, glaucoma, and several other neurodegenerative disorders. Mechanisms of calcium mishandling in these diseases are discussed in this chapter by focusing on HD as an example of a monogenic disease and AD as a multifactorial disease. As aberra
APA, Harvard, Vancouver, ISO, and other styles
3

Gan, Li. Cellular Mechanisms of Dementia. Edited by Dennis S. Charney, Eric J. Nestler, Pamela Sklar, and Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0054.

Full text
Abstract:
Neurodegenerative dementias, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Frontotemporal dementia (FTD), pose enormous challenges for our aging society. Genetic and mechanistic studies have revealed common molecular and cellular pathways, including imbalanced proteostasis and aberrant innate immune responses. Key pathogens in AD, PD, and FTD accumulate and spread from one brain region to another, resulting in network dysfunction and cognitive decline. These diseases are multifactorial, caused by interactions among multiple genetic, epigenetic, and environmental factors and
APA, Harvard, Vancouver, ISO, and other styles
4

Baglietto-Vargas, David, Rahasson R. Ager, Rodrigo Medeiros, and Frank M. LaFerla. Animal Models of Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0014.

Full text
Abstract:
The incidence and prevalence of neurodegenerative disorders (e.g., Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), etc.) are growing rapidly due to increasing life expectancy. Researchers over the past two decades have focused their efforts on the development of animal models to dissect the molecular mechanisms underlying neurodegenerative disorders. Existing models, however, do not fully replicate the symptomatic and pathological features of human diseases. This chapter focuses on animal models of AD, as this disorder is the most prevalent of the brain degen
APA, Harvard, Vancouver, ISO, and other styles
5

Nageshwaran, Sathiji, Heather C. Wilson, Anthony Dickenson, and David Ledingham. Dementia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199664368.003.0011.

Full text
Abstract:
This chapter discusses the clinical features and evidence-based pharmacological management of dementia disorders (Alzheimer’s disease (AD), vascular dementia, dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), frontotemporal dementia (FTD), mixed dementia, and mild cognitive impairment (MCI)).
APA, Harvard, Vancouver, ISO, and other styles
6

Lei, Peng, Scott Ayton, and Ashley I. Bush. Metal-Protein Attenuating Compounds in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0015.

Full text
Abstract:
Neurodegenerative disorders including Alzheimer’s (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are progressive diseases of the aging population with currently few therapeutic options. While aggregation and deposition of disease-specific proteins link the pathologies of these diseases, targeting these aggregating proteins with therapeutics has not yet been successful in clinical trial. This chapter profiles metals (copper, zinc, and iron) as alternative drug targets for neurodegeneration. Complex changes to metals occur in these neurodegener
APA, Harvard, Vancouver, ISO, and other styles
7

Cummings, Jeffrey L., and Kate Zhong. Clinical Trials and Drug Development in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0018.

Full text
Abstract:
This chapter describes the common therapeutic targets, approaches to clinical trial design, biomarkers, and therapeutic interventions across neurodegenerative disorders (NDDs). Each unique NDD-Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), etc.-has a unique phenotype associated with the regional cell population most affected. Each disease, however, is associated with protein misfolding, oxidation, inflammation, apoptosis, and cell death. If vulnerable cell populations include transmitter source nuclei, transmitter deficits also emerge (e.g. cholinergic
APA, Harvard, Vancouver, ISO, and other styles
8

Safar, Jiri G. Prion Paradigm of Human Neurodegenerative Diseases Caused by Protein Misfolding. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0005.

Full text
Abstract:
Data accumulated from different laboratories argue that a growing number of proteins causing neurodegeneration share certain characteristics with prions. Prion-like particles were produced from synthetic amyloid beta (Aβ‎) peptides of Alzheimer’s disease (AD), from recombinant α‎-synuclein linked to Parkinson’s disease (PD), and from recombinant tau associated with frontotemporal dementias (FTD). Evidence from human prions reveals that variable disease phenotypes, rates of propagation, and targeting of different brain structures are determined by distinct conformers (strains) of pathogenic pri
APA, Harvard, Vancouver, ISO, and other styles
9

McBurney, John W. Pesticides and Neurodegenerative Disorders. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190490911.003.0008.

Full text
Abstract:
Neurodegenerative diseases, which are characterized by neuronal degeneration, include Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS). Their worldwide prevalence is increasing as the global population ages. The causes reflect interactions between genetics and environmental factors such as increasing urbanization, industrialization, and widespread use of chemicals, including insecticides, fungicides, and herbicides. Epidemiologic data suggest that exposure to many of these pesticides increases the risk of neurodegeneration. The best-defined mechanism for
APA, Harvard, Vancouver, ISO, and other styles
10

Piggott, Margaret Ann. Neurochemical pathology of dementia. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199644957.003.0007.

Full text
Abstract:
This chapter considers the neurodegenerative disorders Alzheimer’s disease (AD), Lewy body dementias (dementia with Lewy bodies (DLB) and Parkinson’s disease dementia(PDD)), frontotemporal dementia (FTD); and also vascular dementia (VaD) which results from cerebrovascular disease. These different conditions, which give rise to dementia syndromes, each have distinct neurochemical pathologies, with important implications for treatment. As increased age is the common risk factor generally associated with dementing illnesses, neurochemical changes are set in the context of the changes which occur
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Parkinson's Disease (AD)"

1

Watson, Mark, Xue Ming, Simi Vincent, et al. "Studies of Central Nervous System Cholinergic Receptors in Alzheimer’s Disease (AD)." In Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases. Springer New York, 1990. http://dx.doi.org/10.1007/978-1-4684-5844-2_112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kotha, Sumasri, Manjari Sriparna, Joel Tyson, Amanda Li, Weiwei He, and Xiaobo Mao. "Emerging Nanotechnology for the Treatment and Diagnosis of Parkinson’s Disease (PD) and Alzheimer’s Disease (AD)." In Stem Cell Biology and Regenerative Medicine. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-49744-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tamegart, Lahcen, Rabii Hilali, Hajar Ouaki, et al. "Astrocytes Reprogramming for Neurodegenerative Disease Management." In Physiology and Function of Glial Cells in Health and Disease. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-9675-6.ch016.

Full text
Abstract:
Neurodegenerative disorders (NDD) are chronic conditions that lead to nerve cells degeneration in the central nervous system. The most common NDD are Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Huntington's disease (HD). Parkinson's disease (PD) is recognized as the second most common neurodegenerative disease after Alzheimer's disease (AD) and Huntington disease (HD). Astrocytes reprogramming has been recently proposed as one of the most important treatments to stop the progression of these neurological diseases. By tar
APA, Harvard, Vancouver, ISO, and other styles
4

M. Olichney, John, Wentao Li, Yasmine Gharbaoui, Alison P. Kwok, and Jade E. Jenkins. "Diagnosis of Dementia with Lewy Bodies: Fluctuations, Biomarkers, and beyond." In Dementia in Parkinson's Disease [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98433.

Full text
Abstract:
Dementia with Lewy bodies (DLB), the second most common cause of dementia, remains a difficult condition to accurately diagnose and manage. Variable involvement of motor and cognitive functions, plus psychiatric and behavioral symptoms, contributes to the difficulty in managing DLB. Additionally, DLB can cause severe sleep disruption through REM sleep behavior disorder, autonomic symptoms, disruptions of olfaction/taste and mood, hallucinations, and more. In this chapter, advances and remaining challenges in the diagnosis of DLB are discussed, including a review of the current consensus criter
APA, Harvard, Vancouver, ISO, and other styles
5

Kumar, Sunil, Ajay Kumar Shukla, Vimal Kumar Yadav, Ankur Srivastava, Deepti Dwivedi, and Satya Prakash Singh. "Immunopathogenesis of Alzheimer’s disease, Parkinson’s Disease, and other Neurodegenerative Diseases." In Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815238754124010006.

Full text
Abstract:
Neurodegenerative diseases are categorized mostly by protein deposits or known hereditary mechanisms, despite recent studies showing overlap and intraindividual variations in these symptoms. A synergistic interaction between pathological proteins advises extensive pathogenic pathways. Animal models and other studies have uncovered the fundamental mechanisms underlying neurodegeneration and cell death, opening up new avenues for future prevention and therapy plans. A multidomain therapy approach that emphasizes the underlying reasons why diseases alike Parkinson's, Alzheimer's, etc. occur. Neur
APA, Harvard, Vancouver, ISO, and other styles
6

Satpathy, Raghunath. "Quantitative Structure-Activity Relationship (QSAR) Study of Potential Phytochemicals for the Development of Drugs Against Neurological Diseases." In Multidisciplinary Applications of Natural Science for Drug Discovery and Integrative Medicine. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-9463-9.ch001.

Full text
Abstract:
Neurological diseases have recently evolved into a global concern and are commonly observed in elderly populations. Common examples of these diseases are Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). The remarkable application of the computational approach in biological sciences has expedited the drug development process from natural compounds that uncover opportunities to develop new medications. In the computer-aided drug design (CADD) process, the quantitative structure-activity relationship (QSAR) method is crucial i
APA, Harvard, Vancouver, ISO, and other styles
7

Seyedebrahimi, Reihaneh, Piao Yang, Maryam Azimzadeh, et al. "Introduction to Neurodegenerative Diseases." In Deep Learning Approaches for Early Diagnosis of Neurodegenerative Diseases. IGI Global, 2024. http://dx.doi.org/10.4018/979-8-3693-1281-0.ch002.

Full text
Abstract:
Neurons are vital for brain function and communication. Neurodegeneration, the irreversible loss of neurons, disrupts brain-body interactions, causing diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and Parkinson's disease (PD). Factors like aging, genetics, and environment contribute to these disorders. They affect various neurons, leading to speech, movement, sensory, and balance issues. Alzheimer's features amyloid plaques affecting memory. Parkinson's stems from midbrain dopaminergic neuron loss, causing tremo
APA, Harvard, Vancouver, ISO, and other styles
8

Steiner-Lim, Genevieve Z., Madilyn Coles, Kayla Jaye, et al. "Medicinal Cannabis for Alzheimer's Disease." In Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-5652-1.ch001.

Full text
Abstract:
Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extracted from Cannabis sativa (cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attenti
APA, Harvard, Vancouver, ISO, and other styles
9

Bourdon, Allen K., Greg Villareal, George Perry, and Clyde F. Phelix. "Alzheimer's and Parkinson's Disease Novel Therapeutic Target." In Research Anthology on Diagnosing and Treating Neurocognitive Disorders. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-3441-0.ch021.

Full text
Abstract:
Thiazolidinedione (TZD) drugs (Takeda Pharmaceuticals and Metabolic Solutions Development Company) targeting inhibition of the mitochondrial pyruvate carrier (MPC) are currently being tested in clinical trials to prevent progression into mild cognitive impairment of Alzheimer's disease (AD) or in the pipeline to prevent neurodegeneration in Parkinson's disease (PD). These have Ki values in the µM range. This study was focused on identifying candidate drug precursors of the natural cinnamic acid products that might have good bioavailability in the nM ranges forming covalent thiol bonds with tar
APA, Harvard, Vancouver, ISO, and other styles
10

Kashif, Mohd, Mohammad Waseem, Poornima D. Vijendra, and Ashok Kumar Pandurangan. "Protective Effects of Cannabis in Neuroinflammation-Mediated Alzheimer's Disease." In Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-5652-1.ch002.

Full text
Abstract:
In recent years, Alzheimer's disease (AD) has been recognized as an age-related neurological disorder wherein neurons degenerate and exhibit abnormal structure and function. Aging is the primary factor in the progression of AD from mild to severe cognitive impairment. No effective targeted therapies are presently available, and treatment is limited to symptomatic management. The neuropathologic hallmarks of the disease include the accumulation of amyloid-beta (Aβ) plaques in brain tissues and the aggregation of hyperphosphorylated-tau proteins (tangles) within neurons. Associated hyperactivati
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Parkinson's Disease (AD)"

1

Pinheiro, Mariana Maciel, Victor Albuquerque, Pedro Albuquerque, Eduardo Maranhão, Jonathan Diniz, and Breno Barbosa. "CORTICOBASAL SYNDROME DUE TO ALZHEIMER’S DISEASE." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda055.

Full text
Abstract:
Background: Corticobasal Syndrome (CBS) is a neurodegenerative syndrome that combines cortical and cognitive deficits secondary to different underlying pathological entities. Objectives: to report an early onset dementia case fulfilling criteria of probable CBS due to Alzheimer’s Disease (AD) based on biomarkers and neuroimaging. Methods: case report. Results: a 57-yearsold woman with college-level education and 18 months of cognitive decline. The first symptom was progressive inability to change gears in her car, followed by difficulties to get dressed, cognitive and motor complaints. Neurolo
APA, Harvard, Vancouver, ISO, and other styles
2

Ferreira, João Henrique Fregadolli, Amanda Maieski, Caio Disserol, and Helio Afonso Ghizoni Teive. "Corticobasal syndrome with Balint syndrome: a clue for Alzheimer disease pathology." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.712.

Full text
Abstract:
Context: Balint syndrome (BS), first described in 1909, has three core features: optic ataxia, oculomotor apraxia and simultanagnosia, and has been described after various conditions amongst vascular, infectious, demyelinating and degenerative diseases1 . It has already been reported concomitant with corticobasal syndrome (CBS)2 . Case report: 59 year-old male without history of previous diseases presented with behavior changes in the last two years. He had a previous diagnosis of “stroke” because frequent falls to the left side and difficulty in using his left hand for simple daily activities
APA, Harvard, Vancouver, ISO, and other styles
3

Oliveira, Paloma Abrantes de, Diogo Abrantes de Oliveira, and Isabelle Magalhães Guedes Freitas. "Deep brain stimulation of the fornix as a therapeutic approach for Alzheimer’s disease: Systematic Review." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.168.

Full text
Abstract:
INTRODUCTION: Alzheimer’s disease (AD) is a disorder characterized by cognitive impairment. The brain network in DA can be interrupted by deficiencies in glucose metabolismo. Deep brain stimulation (DBS) is used in Parkinson’s disease (PM), once it modulates motor circuits. Considering this potential, the benefits of this approach in DA must be evaluated1,2. OBJECTIVE: To investigate the potential benefit of stimulating the cerebral fornix (CF) through DBS for patients with AD. METHODS: Controlled and randomized clinical trials (ECCR), in English, performed on humans, in the last 5 years, inde
APA, Harvard, Vancouver, ISO, and other styles
4

G, Sivaranjani, Shilpa D, and Sadasivam K. "Evaluating the Reactive Sites, Topological Analysis of the Flavone and Isoflavone Compound – A DFT Study." In The Second National Conference on Emerging Materials for Sustainable Future. Asian Research Association, 2024. http://dx.doi.org/10.54392/ara24119.

Full text
Abstract:
The rapid increase of free radicals (solitary pairs of the electron) population in the human system leads to the production of oxidative stress OS, it is the foremost initiator in simulating the infinite number of diseases in the human system, such as Parkinson’s disease, Alzheimer’s disease AD, amyotrophic lateral sclerosis ALS, multiple sclerosis, depression and memory loss as well as it disturbs the cellular arrangements like lipids, proteins, lipoproteins and deoxyribonucleic acid DNA. The generation of free radical population is terminated by donating an electron to it, these electrons ar
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Parkinson's Disease (AD)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography